{
    "nctId": "NCT05302778",
    "briefTitle": "Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer",
    "officialTitle": "Observational Study Evaluating the Role of Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "Progression-free survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Performance status according to ECOG equal to 0-2\n* Locally advanced or triple negative metastatic breast cancer (HR- and HER2-) confirmed histologically\n* Progressing after first-line chemotherapy for advanced disease\n* Previous anthracyclines and taxanes therapy (in an adjuvant, neoadjuvant or metastatic), unless the patient is ineligible to receive such treatments\n* Treatment with Eribulin mesylate since 2017, in accordance with AIFA indications\n* Adequate haematological, renal and hepatic function, as per clinical practice\n* Written informed consent\n\nExclusion Criteria:\n\n* Breast cancer HER2 + or HR +\n* Treatment with Eribulin in the context of clinical studies\n* Patients unsuitable for treatment with Eribulin\n* Diagnosis of other malignancies in the two years prior to enrollment, with one exception of adequately treated localized basal cell or squamous cell carcinomas of the skin o cervical carcinomas undergoing curative treatment",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}